UY35785A - Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) - Google Patents
Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)Info
- Publication number
- UY35785A UY35785A UY0001035785A UY35785A UY35785A UY 35785 A UY35785 A UY 35785A UY 0001035785 A UY0001035785 A UY 0001035785A UY 35785 A UY35785 A UY 35785A UY 35785 A UY35785 A UY 35785A
- Authority
- UY
- Uruguay
- Prior art keywords
- glyt1
- piperazine derivatives
- glicine
- modulators
- conveyor
- Prior art date
Links
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title abstract 2
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000004885 piperazines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las presentes invenciones se refieren a derivados sustituidos de piperazina de la Fórmula general (I) y a la fabricación de dichos compuestos, las composiciones farmacéuticas quecomprenden un compuesto de acuerdo con la Fórmula general (I), y el uso de dichos compuestos para el tratamiento de diversas condiciones médicas relacionadas con el transportador de glicina-1 (GlyT1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13188904 | 2013-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35785A true UY35785A (es) | 2015-04-30 |
Family
ID=49354583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035785A UY35785A (es) | 2013-10-16 | 2014-10-16 | Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9233953B2 (es) |
| EP (1) | EP3057963B1 (es) |
| JP (1) | JP6483105B2 (es) |
| KR (1) | KR102281284B1 (es) |
| CN (1) | CN105636961B (es) |
| AR (1) | AR098037A1 (es) |
| AU (1) | AU2014336258B2 (es) |
| BR (1) | BR112016008062B1 (es) |
| CA (1) | CA2926754C (es) |
| CL (1) | CL2016000884A1 (es) |
| DK (1) | DK3057963T3 (es) |
| EA (1) | EA029313B1 (es) |
| ES (1) | ES2745555T3 (es) |
| HU (1) | HUE047044T2 (es) |
| IL (1) | IL244693B (es) |
| MX (1) | MX370006B (es) |
| PH (1) | PH12016500577A1 (es) |
| PL (1) | PL3057963T3 (es) |
| TW (1) | TW201609716A (es) |
| UY (1) | UY35785A (es) |
| WO (1) | WO2015055698A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106854189A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种哌嗪化合物的合成方法 |
| CN107778257A (zh) * | 2016-08-29 | 2018-03-09 | 湖南华腾制药有限公司 | 一种哌嗪衍生物的合成方法 |
| CN106977463A (zh) * | 2017-05-31 | 2017-07-25 | 湖南华腾制药有限公司 | 一种联苯取代哌嗪衍生物的合成方法 |
| CN107417679A (zh) * | 2017-08-04 | 2017-12-01 | 河南农业大学 | 1,3‑唑类取代吡嗪类化合物的制备方法 |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| GB0505085D0 (en) * | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
| AR053712A1 (es) * | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
| US9346809B2 (en) | 2009-07-08 | 2016-05-24 | Leo Pharma A/S | Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors |
-
2014
- 2014-10-14 US US14/513,918 patent/US9233953B2/en active Active
- 2014-10-15 AU AU2014336258A patent/AU2014336258B2/en active Active
- 2014-10-15 EA EA201600323A patent/EA029313B1/ru not_active IP Right Cessation
- 2014-10-15 DK DK14784235.5T patent/DK3057963T3/da active
- 2014-10-15 CA CA2926754A patent/CA2926754C/en active Active
- 2014-10-15 KR KR1020167012860A patent/KR102281284B1/ko active IP Right Grant
- 2014-10-15 AR ARP140103834A patent/AR098037A1/es unknown
- 2014-10-15 BR BR112016008062-9A patent/BR112016008062B1/pt active IP Right Grant
- 2014-10-15 EP EP14784235.5A patent/EP3057963B1/en active Active
- 2014-10-15 HU HUE14784235A patent/HUE047044T2/hu unknown
- 2014-10-15 PL PL14784235T patent/PL3057963T3/pl unknown
- 2014-10-15 MX MX2016004847A patent/MX370006B/es active IP Right Grant
- 2014-10-15 WO PCT/EP2014/072085 patent/WO2015055698A1/en active Application Filing
- 2014-10-15 CN CN201480056368.8A patent/CN105636961B/zh active Active
- 2014-10-15 ES ES14784235T patent/ES2745555T3/es active Active
- 2014-10-15 JP JP2016523968A patent/JP6483105B2/ja active Active
- 2014-10-15 TW TW103135739A patent/TW201609716A/zh unknown
- 2014-10-16 UY UY0001035785A patent/UY35785A/es unknown
-
2016
- 2016-03-21 IL IL244693A patent/IL244693B/en active IP Right Grant
- 2016-03-30 PH PH12016500577A patent/PH12016500577A1/en unknown
- 2016-04-14 CL CL2016000884A patent/CL2016000884A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150105397A1 (en) | 2015-04-16 |
| AR098037A1 (es) | 2016-04-27 |
| KR102281284B1 (ko) | 2021-07-23 |
| CN105636961A (zh) | 2016-06-01 |
| CA2926754A1 (en) | 2015-04-23 |
| AU2014336258A1 (en) | 2016-04-14 |
| DK3057963T3 (da) | 2019-09-16 |
| EP3057963A1 (en) | 2016-08-24 |
| NZ718251A (en) | 2021-02-26 |
| EA029313B1 (ru) | 2018-03-30 |
| BR112016008062B1 (pt) | 2022-11-16 |
| JP6483105B2 (ja) | 2019-03-13 |
| EP3057963B1 (en) | 2019-06-19 |
| CL2016000884A1 (es) | 2016-12-30 |
| IL244693B (en) | 2019-08-29 |
| JP2016533368A (ja) | 2016-10-27 |
| TW201609716A (zh) | 2016-03-16 |
| IL244693A0 (en) | 2016-04-21 |
| CN105636961B (zh) | 2019-11-05 |
| AU2014336258B2 (en) | 2018-07-12 |
| PL3057963T3 (pl) | 2019-12-31 |
| WO2015055698A1 (en) | 2015-04-23 |
| EA201600323A1 (ru) | 2016-10-31 |
| ES2745555T3 (es) | 2020-03-02 |
| BR112016008062A2 (es) | 2017-08-01 |
| PH12016500577B1 (en) | 2016-06-20 |
| HUE047044T2 (hu) | 2020-04-28 |
| MX2016004847A (es) | 2016-07-19 |
| PH12016500577A1 (en) | 2016-06-20 |
| US9233953B2 (en) | 2016-01-12 |
| CA2926754C (en) | 2021-09-14 |
| KR20160062187A (ko) | 2016-06-01 |
| MX370006B (es) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| DOP2017000304A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CU20140081A7 (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO6781507A2 (es) | Novedosos derivados heterociclicos | |
| CR20150447A (es) | Nuevos derivados de pirazol | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| CU20170085A7 (es) | Derivados de imidazolidindiona para el tratamiento de la osteoartritis | |
| CR20150440A (es) | Nuevos derivados de piridina | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| CR20150511A (es) | Nuevos derivados de purina | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| BR112017012005A2 (pt) | compostos orgânicos | |
| CR20160448A (es) | Nuevos derivados de piridina |